On 3 February 2015, the FDA in the United States granted accelerated approval to use Palbociclib for the treatment of advanced breast cancer in postmenopausal women who have an estrogen receptor (ER)+/human epidermal growth factor receptor 2-negative (HER2-) status [8]. This evidence concerns the gene ESR1 and breast carcinoma.